Utilization of Liquid Chromatography Mass Spectrometry Analyses to Identify LKB1-APC Interaction in Modulating Wnt/β-catenin Pathway of Lung Cancer Cells
Overview
Authors
Affiliations
Unlabelled: STK11/LKB1, a serine/threonine protein kinase and tumor suppressor, is a key upstream kinase of adenine monophosphate-activated protein kinase, which is a kinase involved in controlling cell polarity and maintaining cellular energy homeostasis. LKB1 is mutated in a significant number of Peutz-Jeghers syndrome (PJS) cases and sporadic cancers, and is most frequently mutated in lung adenocarcinomas; however, little is known about how LKB1 is involved in lung cancer progression. In this study, immunoprecipitation-HPLC tandem mass spectrometry (IP-LC-MS/MS) was performed to identify novel proteins interacting with LKB1 in lung cancer. Interestingly, many LKB1-interacting proteins acquired from the LC-MS/MS approach were mapped, using MetaCore pathway analysis, to the cystic fibrosis transmembrane conductance regulator activation pathway. Moreover, it was determined that LKB1 directly interacts with APC, and this LKB1-APC interaction was further confirmed by reverse immunoprecipitation assays, but GSK3β was dispensable for the association of LKB1 and APC. Importantly, LKB1 binds to APC to suppress the Wnt/β-catenin signaling pathway, which is known to be involved in cell proliferation and migration. Subsequent analysis of the downstream targets of the Wnt/TCF pathway led to the identification of several Wnt-regulated genes, such as CD44, COX-2, survivin, and c-Myc, whose expression levels are downregulated by LKB1. In summary, these results demonstrate that LKB1 regulates the Wnt pathway through a direct interaction with APC to suppress the tumorigenic/metastatic potential of lung tumors.
Implications: LKB1 status influences the molecular circuitry (Wnt/β-catenin pathway), cellular biology, and may serve as a potential therapeutic node in genetically defined subsets of lung cancer.
Wnt/β-catenin signaling in the development and therapeutic resistance of non-small cell lung cancer.
Zhang Z, Westover D, Tang Z, Liu Y, Sun J, Sun Y J Transl Med. 2024; 22(1):565.
PMID: 38872189 PMC: 11170811. DOI: 10.1186/s12967-024-05380-8.
Fang K, Hung H, Lau N, Chi J, Wu D, Cheng K Cancers (Basel). 2023; 15(24).
PMID: 38136437 PMC: 10741874. DOI: 10.3390/cancers15245893.
Inhibition of β-Catenin Activity Abolishes LKB1 Loss-Driven Pancreatic Cystadenoma in Mice.
Hsieh M, Weng C, Lin Y, Wu C, Chen L, Cheng K Int J Mol Sci. 2021; 22(9).
PMID: 33924999 PMC: 8125161. DOI: 10.3390/ijms22094649.
Kuo M, Fang P, Kuo S, Chen A, Huang Y Int J Mol Sci. 2021; 22(1).
PMID: 33401599 PMC: 7796155. DOI: 10.3390/ijms22010422.
Current Landscape of Epigenetics in Lung Cancer: Focus on the Mechanism and Application.
Shi Y, Sheng D, Cheng L, Song X J Oncol. 2020; 2019:8107318.
PMID: 31889956 PMC: 6930737. DOI: 10.1155/2019/8107318.